Xiao, Yinglian and Zhang, Shutian and Dai, Ning and Fei, Guijun and Goh, Khean Lee and Chun, Hoon Jai and Sheu, Bor Shyang and Chong, Chui Fung and Funao, Nobuo and Zhou, Wen and Chen, Minhu (2019) Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut, 69 (2). pp. 224-230. ISSN 0017-5749, DOI https://doi.org/10.1136/gutjnl-2019-318365.
Full text not available from this repository.Abstract
Objective To establish the non-inferior efficacy of vonoprazan versus lansoprazole in the treatment of Asian patients with erosive oesophagitis (EO). Design In this phase III, double-blind, multicentre study, patients with endoscopically confirmed EO were randomised 1:1 to receive vonoprazan 20 mg or lansoprazole 30 mg, once daily for up to 8 weeks. The primary endpoint was EO healing rate at 8 weeks. The secondary endpoints were EO healing rates at 2 and 4 weeks. Safety endpoints included treatment-emergent adverse events (TEAEs). Results In the vonoprazan (n=238) and lansoprazole (n=230) arms, 8-week EO healing rates were 92.4% and 91.3%, respectively (difference 1.1% (95% CI-3.822% to 6.087%)). The respective 2-week EO healing rates were 75.0% and 67.8% (difference 7.2% (95% CI-1.054% to 15.371%)), and the respective 4-week EO healing rates were 85.3% and 83.5% (difference 1.8% (95% CI-4.763% to 8.395%)). In patients with baseline Los Angeles classification grade C/D, 2-week, 4-week and 8-week EO healing rates were higher with vonoprazan versus lansoprazole (2 weeks: 62.2% vs 51.5%, difference 10.6% (95% CI-5.708% to 27.002%); 4 weeks: 73.3% vs 67.2%, difference 6.2% (95% CI-8.884 to 21.223); and 8 weeks: 84.0% vs 80.6%, difference 3.4% (95% CI-9.187% to 15.993%)). Overall, EO healing rates appeared higher with vonoprazan versus lansoprazole. TEAE rates were 38.1% and 36.6% in the vonoprazan and lansoprazole group, respectively. Conclusion Our findings demonstrate the non-inferior efficacy of vonoprazan versus lansoprazole in terms of EO healing rate at 8 weeks in this population. Safety outcomes were similar in the two treatment arms. © 2020 Author(s).
| Item Type: | Article |
|---|---|
| Funders: | Takeda Pharmaceutical company |
| Uncontrolled Keywords: | erosive oesophagitis; gastric acid; gastro-oesophageal reflux disease; proton pump inhibition |
| Subjects: | R Medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 09 Jun 2020 06:16 |
| Last Modified: | 09 Jun 2020 06:16 |
| URI: | http://eprints.um.edu.my/id/eprint/24749 |
Actions (login required)
 |
View Item |
